Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to perform diagnostic practices with high diagnostic accuracy and acquire comparable typing data from C. difficile isolates.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
In 2019, 8 874 (7.4%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
Between 2018 and 2020, nearly 20 000 surgical site infections (SSIs) were reported from a total of over 1.2 million surgical procedures in 13 EU/EEA countries participating in ECDC-coordinated SSI surveillance. Over 2 500 hospitals are part of this surveillance network.
In 2018, 9 860 (7.8%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection or urinary tract infection).
The 2016–2017 ECDC point prevalence survey was the second EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
This document presents the estimated incidence of bloodstream infections (BSI) with three key antibiotic-resistant bacteria, at country level in EU/EEA countries, using public data sources.